The global burden of chronic disease is a growing issue that impacts people, health systems and economies around the world, with chronic diseases accounting for 74% of deaths globally.

Docomed is a medical device technology company focused on improving the management of patients with chronic diseases.

Docomed’s ARTEMIS™ is a unique, AI-optimised cardio-respiratory medical device technology stack designed to support the diagnosis and preventative management of patients with chronic diseases in their homes and communities. This technology aims to enhance the clinical delivery of care, leading to an improved quality of life for patients, their dependents, caregivers and clinical or nursing staff. It empowers earlier intervention, reduces emergency visits and lightens the load on strained health systems.

Using the body as a sensor, Docomed’s technology identifies a rich set of cardiac and respiratory metrics and diagnosis, which directly indicates chronic disease status and deterioration, traditionally only available via hospital-based examination and tests.

Designed to interface with clinical systems such as remote monitoring solutions – Docomed’s scalable and unique technology stack integrates wearable and handheld medical devices with cloud-based AI analytics, producing real-time ECG, respiratory metrics and predictive insights. Clinicians can receive decision-ready data without requiring hospital-based equipment.

With FDA and MDR approvals underway and a highly experienced team spanning clinical innovation, AI, regulatory strategy and remote care deployment, Docomed is uniquely positioned to support the next generation of remote patient monitoring.

This is precision-driven, scalable care—designed for an aging population and a stretched clinical workforce. Backed by a seasoned leadership team with 160+ years in healthcare, Docomed is positioned to lead the next generation of remote patient care—one beat at a time.

Docomed Ltd

Org chart

Teams

Offices